Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Addition of Anti‐leukotriene Agents to Inhaled Corticosteroids in Children With Persistent Asthma." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439035/all/Addition_of_anti‐leukotriene_agents_to_inhaled_corticosteroids_in_children_with_persistent_asthma.
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439035/all/Addition_of_anti‐leukotriene_agents_to_inhaled_corticosteroids_in_children_with_persistent_asthma. Accessed January 19, 2026.
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439035/all/Addition_of_anti‐leukotriene_agents_to_inhaled_corticosteroids_in_children_with_persistent_asthma
Addition of Anti‐leukotriene Agents to Inhaled Corticosteroids in Children With Persistent Asthma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439035/all/Addition_of_anti‐leukotriene_agents_to_inhaled_corticosteroids_in_children_with_persistent_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
ID - 439035
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439035/all/Addition_of_anti‐leukotriene_agents_to_inhaled_corticosteroids_in_children_with_persistent_asthma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -

Cochrane Abstracts

